Get started
Author

Erin L. Filbert

Observed names: Erin Filbert, Erin L Filbert, Filbert, Erin Lindsay
ORCID: 0000-0001-5077-9030
Observed ORCID: 0000-0001-5077-9030
OpenAlex ID: A5062448287
Scaffold proteins and immune-cell signalling
2008 · Andrey S. Shaw, Erin L. Filbert · Nature reviews. Immunology · 215
Growth hormone enhances thymic function in HIV-1–infected adults
2008 · Laura A. Napolitano, Diane Schmidt, et al. · Journal of Clinical Investigation · 181
PDF
Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF
2011 · Jiancheng Hu, Haiyang Yu, et al. · Proceedings of the National Academy of Sciences · 135
PDF
Stathmin Regulates Microtubule Dynamics and Microtubule Organizing Center Polarization in Activated T Cells
2012 · Erin L Filbert, Marie Le Borgne, et al. · The Journal of Immunology · 56
APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application
2021 · Erin L. Filbert, Pia K. Björck, et al. · Cancer Immunology Immunotherapy · 40
PDF
The death effector domain protein PEA‐15 negatively regulates T‐cell receptor signaling
2010 · Sandra Pastorino, Hemamalini Renganathan, et al. · The FASEB Journal · 23
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
2025 · Andrew H. Ko, Joseph Chao, et al. · Cancer Research Communications · 10
PDF
Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer
2024 · Maira Soto, Erin L. Filbert, et al. · Cancer Research Communications · 10
PDF
Abstract LB175: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression
2021 · Sushma Krishnan, Ryan Alvarado, et al. · Cancer Research · 9
693 APX601, a Novel TNFR2 antagonist antibody for cancer immunotherapy
2020 · Erin Filbert, Sushma Krishnan, et al. · Journal for ImmunoTherapy of Cancer · 9
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy
2021 · Sarah Weiss, Mario Sznol, et al. · Journal for ImmunoTherapy of Cancer · 8
PDF
Kinase Suppressor of Ras 1 Is Not Required for the Generation of Regulatory and Memory T Cells
2013 · Marie Le Borgne, Erin L. Filbert, et al. · PLoS ONE · 6
PDF
Kinase suppressor of Ras 1 is required for full ERK activation in thymocytes but not for thymocyte selection
2010 · Erin L. Filbert, AnhCo Nguyen, et al. · European Journal of Immunology · 6
PDF
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy
2024 · Jonathan Barratt, Biruh Workeneh, et al. · Journal of the American Society of Nephrology · 3
Abstract 5004: APX005M, a humanized anti-CD40 antibody with strong immune-modulatory activities capable of tumor eradication in vivo
2016 · Pia Björck, Erin Filbert, et al. · Cancer Research · 3
The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
2015 · Pia Bjorck, Erin Filbert, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.
2023 · Maira Soto, Erin L Filbert, et al. · Journal of Clinical Oncology · 2
Abstract LB177: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor
2021 · Ryan Alvarado, Sushma Krishnan, et al. · Cancer Research · 1
188 Novel Anti-SIRpalpha antibodies with differentiated characteristics as promising cancer therapeutics
2020 · Minu K Srivastava, Ryan Alvarado, et al. · Journal for ImmunoTherapy of Cancer · 1
WCN26-5830 A TRANSLATIONAL FRAMEWORK TO PREDICT CLINICAL RESPONSES TO APRIL BLOCKADE FOR DEVELOPMENT OF JADE101, AN ANTI-APRIL MONOCLONAL ANTIBODY IN IgAN
2026 · Li Li, Todd DeVries, et al. · Kidney International Reports
PDF
#2438 Discovery and characterization of JADE101, an ultra-high affinity, half-life extended anti-APRIL monoclonal antibody for the treatment of IgAN
2025 · Erin Filbert, Brandon Gufford, et al. · Nephrology Dialysis Transplantation
PDF
Translational Framework to Predict Clinical Responses to APRIL Blockade for Development of JADE101, an Anti-APRIL Monoclonal Antibody in IgAN
2025 · Brandon T Gufford, Todd DeVries, et al. · Journal of the American Society of Nephrology
Nonclinical Safety Profile of JADE101, a Half-Life Extended Fully Human Monoclonal Antibody Targeting APRIL for the Treatment of IgAN
2025 · Ashley McCord, Maira Soto, et al. · Journal of the American Society of Nephrology
Data from A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
2025 · Andrew H. Ko, Joseph Chao, et al.
Supplementary Table 1 from A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
2025 · Andrew H. Ko, Joseph Chao, et al.
Works count: 52
Citation count: 721
H-index: 9
I10-index: 8
Year
Topic
Type